Boehringer Ingelheim receives approval for SENVELGO in Europe the first oral liquid medication for diabetic cats
Boehringer Ingelheim a global leader in animal health has received marketing authorization from the European Commission for SENVELGO active ingredient velagliflozin marking a significant step for the treatment of feline diabetes in Europe.